# Pharma Max

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharma-max

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.pharmamaxcorp.com
- Latest round: Series B (Sep 8, 2021)
- Investors on record: 5

## About

Based in Jiangsu, China and founded in 2010, Pharma Max is a developer of oronasal drugs, focusing on the research and development, production and sales of new drugs and medical devices. In September 2021, the company completed series B+ funding from China Capital Management, Shanghai Kangcheng Investment Management and Chongning Capital. The company has established a research and development and production platform for liquid preparations, solid preparations, microspheres and liposomes. The founder, chairman of board and president Dr. Zhijun Jiang, he has been engaged in bio-pharmaceutical innovation research for more than 30 years, he served as vice president of research and development and operation of Teva.

The company's medical device products Bi Min Ling, Sai Li Ping, Gan Qing have been approved for listing.

The latest funding will be used to accelerate the research and development of respiratory preparations, mental sustained-release preparations, microsphere preparations and liposomes, as well as the construction of GMP workshop.

## Funding rounds

- Series B, Sep 8, 2021 — China Capital Management, Shanghai Kangcheng Investment Management, Chongning Capital
- Series B, Apr 17, 2018 — Hanfor Capital, Efung Capital

## Investors

- Hanfor Capital (https://capitalatlas.ai/funds/hanfor-capital) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series B
- Shanghai Kangcheng Investment Management — Series B
- Chongning Capital (https://capitalatlas.ai/funds/chongning-capital) — Series B